Search

Your search keyword '"Abdelhakim Ahmed-Belkacem"' showing total 2 results
Start Over Author "Abdelhakim Ahmed-Belkacem" Journal nature communications
2 results on '"Abdelhakim Ahmed-Belkacem"'

1. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities

Author

Abdelhakim Ahmed-Belkacem, Lionel Colliandre, Nazim Ahnou, Quentin Nevers, Muriel Gelin, Yannick Bessin, Rozenn Brillet, Olivier Cala, Dominique Douguet, William Bourguet, Isabelle Krimm, Jean-Michel Pawlotsky, and Jean- François Guichou

Subjects
Science
Abstract

Cyclophilins play a key role in the life cycle of many viruses and represent important drug targets for broad-spectrum antiviral therapies. Here, the authors use fragment-based drug discovery to develop non-peptidic inhibitors of human cyclophilins with high activity against replication of a number of viral families.

Published
2016
Full Text
View/download PDF

2. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities

Author

Lionel Colliandre, Abdelhakim Ahmed-Belkacem, Dominique Douguet, Olivier Cala, William Bourguet, Quentin Nevers, Muriel Gelin, Isabelle Krimm, Rozenn Brillet, Yannick Bessin, Nazim Ahnou, Jean-Michel Pawlotsky, Jean-François Guichou, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Centre de Biochimie Structurale [Montpellier] (CBS), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), ISA - Méthodes et criblage RMN pour les molécules bioactives, Institut des Sciences Analytiques (ISA), Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), This work was supported by the French Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-INSB-05-01, the Fonds Europeen de Developpement Economique et Regional (FEDER) Number 48748, the Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS) and the Fondation pour la Recherche Medicale (FRM)., ANR-10-INBS-0005,FRISBI,Infrastructure Française pour la Biologie Structurale Intégrée(2010), Bussy, Agnès, Infrastructure Française pour la Biologie Structurale Intégrée - - FRISBI2010 - ANR-10-INBS-0005 - INBS - VALID, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, [CHIM.ANAL] Chemical Sciences/Analytical chemistry, CYCLOSPORINE-A, Hepatitis C virus, Science, General Physics and Astronomy, Isomerase, Biology, medicine.disease_cause, General Biochemistry, Genetics and Molecular Biology, Article, MECHANISMS, T-CELL-ACTIVATION, 03 medical and health sciences, DESIGN, [CHIM.ANAL]Chemical Sciences/Analytical chemistry, medicine, polycyclic compounds, Peptide bond, Cyclophilin, Alisporivir, Multidisciplinary, Drug discovery, General Chemistry, ALISPORIVIR, Antivirals, Small molecule, Virology, 3. Good health, APOPTOSIS, GENOTYPE, DRUG DISCOVERY, MITOCHONDRIAL PERMEABILITY TRANSITION, 030104 developmental biology, Biochemistry, REPLICATION, Nucleic acid, Structure-based drug design, Pathogens
Abstract

Cyclophilins are peptidyl-prolyl cis/trans isomerases (PPIase) that catalyse the interconversion of the peptide bond at proline residues. Several cyclophilins play a pivotal role in the life cycle of a number of viruses. The existing cyclophilin inhibitors, all derived from cyclosporine A or sanglifehrin A, have disadvantages, including their size, potential for side effects unrelated to cyclophilin inhibition and drug–drug interactions, unclear antiviral spectrum and manufacturing issues. Here we use a fragment-based drug discovery approach using nucleic magnetic resonance, X-ray crystallography and structure-based compound optimization to generate a new family of non-peptidic, small-molecule cyclophilin inhibitors with potent in vitro PPIase inhibitory activity and antiviral activity against hepatitis C virus, human immunodeficiency virus and coronaviruses. This family of compounds has the potential for broad-spectrum, high-barrier-to-resistance treatment of viral infections., Cyclophilins play a key role in the life cycle of many viruses and represent important drug targets for broad-spectrum antiviral therapies. Here, the authors use fragment-based drug discovery to develop non-peptidic inhibitors of human cyclophilins with high activity against replication of a number of viral families.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results